Acrivon Therapeutics (NASDAQ:ACRV) Earns “Buy” Rating from HC Wainwright

Acrivon Therapeutics (NASDAQ:ACRV)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 110.53% from the stock’s previous close.

ACRV has been the topic of a number of other research reports. LADENBURG THALM/SH SH dropped their price target on Acrivon Therapeutics from $18.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, April 5th. JMP Securities reaffirmed a “market outperform” rating and issued a $14.00 price target on shares of Acrivon Therapeutics in a report on Monday, April 1st. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $18.00 target price on shares of Acrivon Therapeutics in a research report on Monday, April 1st. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Acrivon Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $20.14.

Acrivon Therapeutics Trading Down 3.3 %

NASDAQ ACRV opened at $9.50 on Thursday. Acrivon Therapeutics has a 52 week low of $3.19 and a 52 week high of $14.30. The company has a 50 day moving average price of $6.47 and a 200 day moving average price of $5.33.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.14). As a group, equities analysts forecast that Acrivon Therapeutics will post -3.3 EPS for the current year.

Insider Transactions at Acrivon Therapeutics

In related news, major shareholder Perceptive Advisors Llc purchased 2,353,000 shares of the firm’s stock in a transaction on Thursday, April 11th. The stock was bought at an average cost of $8.50 per share, with a total value of $20,000,500.00. Following the completion of the acquisition, the insider now owns 5,360,858 shares of the company’s stock, valued at approximately $45,567,293. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.30% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Acrivon Therapeutics stock. Exchange Traded Concepts LLC lifted its holdings in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) by 34.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,289 shares of the company’s stock after purchasing an additional 3,370 shares during the period. Exchange Traded Concepts LLC owned about 0.06% of Acrivon Therapeutics worth $65,000 as of its most recent filing with the Securities & Exchange Commission. 71.62% of the stock is owned by institutional investors and hedge funds.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.